Business Context and Reporting Period
This Form 8-K is a current report filed by Renovaro Inc. (not Lunai Bioworks Inc.) on February 28, 2024, regarding corporate governance changes. The registrant is a Delaware corporation with its principal executive offices in Los Angeles, CA, and its common stock trades on The Nasdaq Stock Market under the symbol RENB.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Principal Officer: Luisa Puche tendered her resignation as Chief Financial Officer (CFO), effective March 21, 2024.
- Transition Plan: An experienced Interim-CFO candidate has been identified, and contract negotiations are underway to ensure overlap with Ms. Puche.
- Consulting Role: Ms. Puche has agreed to continue in a consulting role if needed to facilitate a smooth transition.
- Reason for Departure: The resignation is explicitly stated as not being the result of any disagreement with the Company, its management, or the Board of Directors.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies beyond the operational transition of the CFO role. Management expressed appreciation for Ms. Puche's service and wishes her success in future endeavors.
Investor Verification Checklist
- Verify the appointment and start date of the new Interim-CFO.
- Confirm the terms of Ms. Puche's consulting agreement, if finalized.
- Review subsequent filings for any impact on financial reporting timelines or internal controls due to the leadership change.
- Check for any undisclosed disagreements or related party transactions not mentioned in this 8-K.